物質使用障礙治療：2030 年全球市場展望

2025 年全球物質使用障礙 (SUD) 治療市場價值為 116 億美元，預計從 2025 年到 2030 年將以 4.6% 的複合年成長率成長，到 2030 年底達到 146 億美元。

預計到 2025 年，北美物質使用障礙 (SUD) 治療市場規模將達到 42 億美元，從 2025 年到 2030 年將以 4.8% 的複合年成長率成長，到 2030 年底將達到 54 億美元。

預計到 2025 年，亞太地區（APAC）物質使用障礙（SUD）治療市場規模將達到 30 億美元，從 2025 年到 2030 年將以 5.6% 的複合年成長率成長，到 2030 年底將達到 40 億美元。

調查範圍

本報告對全球物質使用障礙（SUD）治療市場進行了詳細分析，並按疾病、藥物和地區進行了細分。 BCC Research 估算了 2024 年（基準年）和 2025 年的市場數據，並預測了 2026 年至 2030 年的市場規模。報告重點關注市場和供應商格局中的關鍵趨勢、挑戰和機遇，並涵蓋了與市場相關的新產品、收購和合作關係。此外，報告還分析了環境、社會和治理（ESG）趨勢。

本報告最後分析了每個疾病領域的競爭格局，並包含主要企業概況介紹。

報告內容

• 數據表 25 和附加表 57
• 全球物質使用障礙治療藥物市場概述與分析
• 全球趨勢分析（包括 2022 年至 2024 年的歷史銷售數據、2025 年的估計值以及到 2030 年的預測複合年成長率）
• 對全球市場的當前市場規模和收入預測進行估算，並按疾病（藥物濫用）、治療方法和地區進行市場佔有率分析。
• 有關市場動態、技術進步、法規、前景和宏觀經濟變數的影響的事實和數據。
• 基於波特五力模型和全球供應鏈分析的見解。
• 專利綜述，重點介紹已註冊和已公佈的主要專利
• 產業結構分析，包括公司市場佔有率和排名、產品佈局、策略舉措、併購活動和創業融資前景。
• 概述永續發展趨勢和ESG進展。重點關注消費者意識，以及主要公司當前的ESG狀況和實踐。
• 業界領先公司的公司簡介，包括 Indivior PLC、Camurus AB、Alkermes、Dr. Reddy's Laboratories Ltd. 和 Braeburn Inc.。

目錄

第1章摘要整理

第2章 市場概覽

• 物質使用障礙概述
• 宏觀經濟因素分析
• 政府撥款和公共醫療保健預算
• 收入不平等和社會經濟地位
• 勞動市場趨勢
• 全球供應鏈動態與非法市場的宏觀經濟學
• 美國關稅的影響
• 波特五力分析
• 新進入者的威脅：中等
• 產業競爭程度：高

第3章 市場動態

• 市場動態
• 市場促進因素
• 物質使用障礙在全球普遍存在。
• 非法藥物的擴散
• 人們越來越意識到物質使用障礙的臨床影響
• 擴大政府和公共衛生領域的干預措施
• 市場挑戰
• 儘管疾病負擔沉重，但治療覆蓋率卻很低。
• 污名和社會障礙
• 市場趨勢
• 過渡到長效和緩釋療法
• 藥物研發創新
• 遠端醫療的擴展
• 數位療法和藥物聯合治療

第4章 監管情勢

• 概述
• 美國
• 主要聯邦機構及其作用
• 歐洲
• 歐洲藥品管理局（EMA）
• 歐盟藥品管理局（EUDA）
• 日本

第5章：新興科技與趨勢

• 新興科技與趨勢
• Glucagon-Like Peptide-1受體促效劑（GLP-1RAs）
• 迷幻劑
• 臨床試驗分析
• 依條件類型
• 依資助者類型
• 處於後期臨床試驗階段的候選藥物

第6章 市場區隔分析

• 細分市場
• 全球物質使用障礙治療市場
• 尼古丁使用障礙
• 尼古丁替代療法
• Varenicline
• 其他
• 鴉片類藥物使用障礙
• Buprenornhine
• 梅塔頓
• 納曲酮
• 酒精使用障礙
• 納曲酮
• Acamprosate
• 其他
• 按地區分類
• 全球物質使用障礙治療市場（按地區分類）
• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 南美洲

第7章 競爭情勢

• 鴉片類藥物使用障礙
• 酒精使用障礙
• 尼古丁使用障礙

第8章 物質使用障礙市場的永續性：從ESG視角看

• ESG概覽
• 物質使用障礙市場特有的關鍵ESG挑戰
• 消除治療方面的差異
• 與當地社區合作並減少歧視
• 減少碳足跡
• 數據透明度和治療結果報告
• 結論

第9章附錄

• 調查方法
• 資訊來源
• 簡稱
• 公司簡介
• ACHIEVE LIFE SCIENCES INC.
• ADIAL PHARMACEUTICALS
• ALKERMES
• BRAEBURN INC.
• CAMURUS AB
• DA-PHARMA
• DR. REDDY'S LABORATORIES LTD.
• ETHYPHARM
• H. LUNDBECK A/S
• INDIVIOR PLC
• KENVUE
• LILLY USA LLC.
• NFL BIOSCIENCES
• OREXO AB（PUBL.）
• PAR HEALTH INC.
• 新興創業公司/市場顛覆者

The global substance use disorder (SUD) treatment market was valued at $11.6 billion in 2025, and it is expected to reach $14.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2030.

The North American substance use disorder (SUD) treatment market was valued at $4.2 billion in 2025, and it is projected to reach $5.4 billion by the end of 2030, at a CAGR of 4.8% from 2025 to 2030.

The APAC substance use disorder (SUD) treatment market was valued at $3 billion in 2025, and it is projected to reach $4 billion by the end of 2030, at a CAGR of 5.6% from 2025 to 2030.

Report Scope

This report presents an in-depth analysis of the global SUD treatment market by conditions, drugs, and geographic markets. BCC Research estimates market data for 2024 (the base year) and 2025 and forecasts values for 2026 through 2030. The report focuses on the major trends, challenges, and opportunities in the market and vendor landscape. It also covers the new products, acquisitions, and collaborations related to the market. The report also analyzes environmental, social, and corporate governance (ESG) developments.

The report concludes with an analysis of the competitive landscape for each condition. There is also a section of profiles of the leading companies.

Report Includes

• 25 data tables and 57 additional tables
• Overview and an analysis of the global market for substance use disorder treatment therapeutics
• Analyses of the global market trends, with historic revenue from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects for the global market, accompanied by a market share analysis by condition (substance abuse), treatment type and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impact of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the current status and ESG practices of leading companies
• Company profiles of major players within the industry, including Indivior PLC, Camurus AB, Alkermes, Dr. Reddy's Laboratories Ltd., and Braeburn Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics
• Emerging Trends
• Analysis by Segment
• Analysis by Region
• Conclusion

Chapter 2 Market Overview

• Substance Use Disorder Overview
• Analysis of Macroeconomic Factors
• Government Funding and Public Healthcare Budgets
• Income Inequality and Socioeconomic Status
• Labor Market Dynamics
• Global Supply Dynamics and the Macroeconomics of Illicit Markets
• Impact of U.S. Tariffs
• Porter's Five Forces Analysis
• Bargaining Power of Buyers: High
• Bargaining Power of Suppliers: Low to Moderate
• Threat of New Entrants: Moderate
• Threat of Substitutes: Moderate
• Industry Rivalry: High

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Widespread Global Prevalence of Substance Use Disorders
• Proliferation of Illicit Drugs
• Increasing Awareness of the Clinical Impact of Substance Use Disorders
• Increasing Government and Public Health Interventions
• Market Challenges
• Low Treatment Penetration Despite High Disease Burden
• Stigma and Social Barriers
• Market Trends
• Shift Toward Long-Acting and Sustained-Release Therapies
• Innovation in Drug Development
• Expansion of Telemedicine
• Digital-Pharmacologic Combination Therapies

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Key Federal Actors and Their Roles
• Europe
• European Medicines Agency (EMA)
• The European Union Drugs Agency (EUDA)
• Japan

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies and Developments
• Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs)
• Psychedelics
• Clinical Trial Analysis
• By Condition Type
• By Funder Type
• Therapeutic Candidates in Late-Stage Clinical Trials

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Substance Use Disorder Treatment Market
• Nicotine Use Disorder
• Nicotine Replacement Therapy
• Varenicline
• Others
• Opioid Use Disorder
• Buprenorphine
• Methadone
• Naltrexone
• Alcohol Use Disorder
• Naltrexone
• Acamprosate
• Others
• Geographic Breakdown
• Global Substance Use Disorder Treatment Market, by Region
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Opioid Use Disorder
• Alcohol Use Disorder
• Nicotine Use Disorder

Chapter 8 Sustainability in Substance Use Disorder Treatment Market: An ESG Perspective

• Introduction to ESG
• Key ESG Issues Specific to the Substance Use Disorder Treatment Market
• Closing the Treatment Gap
• Community Engagement and Stigma Reduction
• Carbon Footprint Reduction
• Data Transparency and Outcomes Reporting
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ACHIEVE LIFE SCIENCES INC.
• ADIAL PHARMACEUTICALS
• ALKERMES
• BRAEBURN INC.
• CAMURUS AB
• DA-PHARMA
• DR. REDDY'S LABORATORIES LTD.
• ETHYPHARM
• H. LUNDBECK A/S
• INDIVIOR PLC
• KENVUE
• LILLY USA LLC.
• NFL BIOSCIENCES
• OREXO AB (PUBL.)
• PAR HEALTH INC.
• Emerging Startups/Market Disruptors

List of Tables

• Summary Table : Global Market for Substance Use Disorder Treatment, by Region, Through 2030
• Table 1 : Substance Use Disorders Prevalence for Key Substances in the U.S., 2023
• Table 2 : The Substance Use Treatment Gap in the U.S., 2024
• Table 3 : Therapeutic Candidates in Phase 3 for Nicotine Use Disorder or Alcohol Use Disorder
• Table 4 : Therapeutic Candidates in Phase 2 for Opioid Use Disorder
• Table 5 : Therapeutic Candidates in Phase 2 for Alcohol Use Disorder
• Table 6 : Therapeutic Candidates in Phase 2 for Nicotine Use Disorder
• Table 7 : Industry-Sponsored Therapeutic Candidates in Phase 2 for Cannabis Use Disorder
• Table 8 : Industry-Sponsored Therapeutic Candidates in Phase 2 for Methamphetamine Use Disorder
• Table 9 : Drug Classes Commonly Associated with Substance-Related Disorders
• Table 10 : Global Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 11 : Global Market for Nicotine Use Disorder Treatment, by Drug Type, Through 2030
• Table 12 : NRT Products
• Table 13 : Global Market for Opioid Use Disorder Treatment, by Drug Type, Through 2030
• Table 14 : FDA-Approved Buprenorphine Medications for Opioid Use Disorder (MOUD)
• Table 15 : OUD Medications: An Overview
• Table 16 : Global Market for Alcohol Use Disorder Treatment, by Drug Type, Through 2030
• Table 17 : Alcohol Use Disorder Medications: An Overview
• Table 18 : Global Market for Substance Use Disorder Treatment, by Region, Through 2030
• Table 19 : North American Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 20 : North American Market for Substance Use Disorder Treatment, by Country, Through 2030
• Table 21 : Substance Use Among the General Population in Canada, 2023
• Table 22 : European Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 23 : European Market for Substance Use Disorder Treatment, by Country, Through 2030
• Table 24 : Share of Adults Who Smoked in 2000 versus 2024 Trends in Prevalence of Tobacco Use Among People Aged 15 Years and Older, by WHO Region
• Table 25 : Adult Substance Misuse Treatment Statistics in the U.K., 2023-2024
• Table 26 : Asia-Pacific Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 27 : Asia-Pacific Market for Substance Use Disorder Treatment, by Country, Through 2030
• Table 28 : Middle East and African Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 29 : Share of Population with Alcohol Use Disorder (2021) versus Drug Use Disorder (2021) versus Smoke or Tobacco Users (2022)
• Table 30 : South American Market for Substance Use Disorder Treatment, by Condition, Through 2030
• Table 31 : Information Sources for this Report
• Table 32 : Abbreviations Used in This Report
• Table 33 : Achieve Life Sciences Inc.: Company Snapshot
• Table 34 : Achieve Life Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 35 : Achieve Life Sciences Inc.: Product Portfolio
• Table 36 : Achieve Life Sciences Inc.: News/Key Developments, 2024-2025
• Table 37 : Adial Pharmaceuticals: Company Snapshot
• Table 38 : Adial Pharmaceuticals: Financial Performance, FY 2023 and 2024
• Table 39 : Adial Pharmaceuticals: Product Portfolio
• Table 40 : Adial Pharmaceuticals: News/Key Developments, 2025
• Table 41 : Alkermes: Company Snapshot
• Table 42 : Alkermes: Financial Performance, FY 2023 and 2024
• Table 43 : Alkermes: Product Portfolio
• Table 44 : Braeburn Inc.: Company Snapshot
• Table 45 : Braeburn Inc.: Product Portfolio
• Table 46 : Camurus AB: Company Snapshot
• Table 47 : Camurus AB: Financial Performance, FY 2023 and 2024
• Table 48 : Camurus AB: Product Portfolio
• Table 49 : Camurus AB: News/Key Developments, 2025
• Table 50 : Da-pharma: Company Snapshot
• Table 51 : Da-pharma: Product Portfolio
• Table 52 : Dr. Reddy's Laboratories Ltd.: Company Snapshot
• Table 53 : Dr. Reddy's Laboratories Ltd.: Financial Performance, FY 2023 and 2024
• Table 54 : Dr. Reddy's Laboratories Ltd.: Product Portfolio
• Table 55 : Dr. Reddy's Laboratories Ltd.: News/Key Developments, 2025
• Table 56 : Ethypharm: Company Snapshot
• Table 57 : Ethypharm: Product Portfolio
• Table 58 : H. Lundbeck A/S: Company Snapshot
• Table 59 : H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
• Table 60 : H. Lundbeck A/S: Product Portfolio
• Table 61 : Indivior PLC: Company Snapshot
• Table 62 : Indivior PLC: Financial Performance, FY 2023 and 2024
• Table 63 : Indivior PLC: Product Portfolio
• Table 64 : Indivior PLC: News/Key Developments, 2025
• Table 65 : Kenvue: Company Snapshot
• Table 66 : Kenvue: Financial Performance, FY 2023 and 2024
• Table 67 : Kenvue: Product Portfolio
• Table 68 : Lilly USA LLC.: Company Snapshot
• Table 69 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
• Table 70 : Lilly USA LLC.: Product Portfolio
• Table 71 : NFL Biosciences: Company Snapshot
• Table 72 : NFL Biosciences: Financial Performance, FY 2023 and 2024
• Table 73 : NFL Biosciences: Product Portfolio
• Table 74 : NFL Biosciences: News/Key Developments, 2025
• Table 75 : Orexo AB (Publ.): Company Snapshot
• Table 76 : Orexo AB (Publ.): Financial Performance, FY 2023 and 2024
• Table 77 : Orexo AB (Publ.): Product Portfolio
• Table 78 : Orexo AB (Publ.): News/Key Developments, 2024-2025
• Table 79 : Par Health Inc.: Company Snapshot
• Table 80 : Par Health Inc.: Product Portfolio
• Table 81 : Emerging Startups/Market Disruptors

List of Figures

• Summary Figure : Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis-Substance Use Disorder Treatment Industry
• Figure 2 : Market Dynamics of Substance Use Disorder Treatment
• Figure 3 : Active Clinical Trials of Substance Use Disorders, by Condition, 2025
• Figure 4 : Active Clinical Trials of Substance Use Disorders, by Funder Type, 2025
• Figure 5 : Global Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 6 : Global Market Shares for Nicotine Use Disorder Treatment, by Drug Type, 2024
• Figure 7 : Global Market Shares for Opioid Use Disorder Treatment, by Drug Type, 2024
• Figure 8 : Global Market Shares for Alcohol Use Disorder Treatment, by Drug Type, 2024
• Figure 9 : Global Market Shares for Substance Use Disorder Treatment, by Region, 2024
• Figure 10 : North American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 11 : North American Market Shares for Substance Use Disorder Treatment, by Country, 2024
• Figure 12 : Number of Americans Aged 12 or Older Using Cigarette or Nicotine Vaping Products
• Figure 13 : European Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 14 : European Market Shares for Substance Use Disorder Treatment, by Country, 2024
• Figure 15 : People in Opioid Agonist Treatment in the EU in 2023, by Type of Medication
• Figure 16 : Total Number of Adults Receiving Treatment for Drugs and/or Alcohol in England
• Figure 17 : Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 18 : Asia-Pacific Market Shares for Substance Use Disorder Treatment, by Country, 2024
• Figure 19 : Middle East and African Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 20 : South American Market Shares for Substance Use Disorder Treatment, by Condition, 2024
• Figure 21 : Global Market Shares for Opioid Use Disorder Treatment Market, by Company, 2024
• Figure 22 : ALKERMES: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : ALKERMES: Revenue Shares, by Country/Region, FY 2024
• Figure 24 : Camurus AB: Revenue Shares, by Business Unit, FY 2024
• Figure 25 : Camurus AB: Revenue Shares, by Country/Region, FY 2024
• Figure 26 : Dr. Reddy's Laboratories Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 27 : Dr. Reddy's Laboratories Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 28 : H. Lundbeck A/S: Revenue Shares, by Business Unit, FY 2024
• Figure 29 : H. Lundbeck A/S: Revenue Shares, by Country/Region, FY 2024
• Figure 30 : Indivior PLC: Revenue Shares, by Business Unit, FY 2024
• Figure 31 : Indivior PLC: Revenue Shares, by Country/Region, FY 2024
• Figure 32 : KENVUE: Revenue Shares, by Business Unit, FY 2024
• Figure 33 : KENVUE: Revenue Shares, by Country/Region, FY 2024
• Figure 34 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
• Figure 35 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
• Figure 36 : Orexo AB (Publ.): Revenue Shares, by Business Unit, FY 2024
• Figure 37 : Orexo AB (Publ.): Revenue Shares, by Country/Region, FY 2024